SPG11

Across TCGA pan-cancer cohorts, SPG11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPG11 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SPG11 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPG11 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, HNSC, and GBM are the cancer types where SPG11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.628	0.925	<.001	35	view →
HNSC	DFS	Median	II,III,IV	0.988	0.883	.005	13	view →
GBM	DFS	Quartile	All	0.493	0.824	.003	8	view →
UCEC	DFS	Quartile	II,III,IV	0.473	0.880	.018	8	view →
LUAD	OS	Quartile	All	0.564	0.879	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPG11–PDAC (DFS)

Open the PDAC breakdown →